These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2659568)

  • 1. Activity of ciprofloxacin against Escherichia coli phagocytosed by monocytes and macrophages.
    Burgaleta C; Moreno T; Loza E
    J Antimicrob Chemother; 1989 Mar; 23(3):460-2. PubMed ID: 2659568
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of a new quinoline derivative, ciprofloxacin, on some professional phagocytic cell functions.
    Delfino D; Bonina L; Berlinghieri MC; Mastroeni P
    Chemioterapia; 1985 Dec; 4(6):463-6. PubMed ID: 2937564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular activity of cefamandole and aztreonam against phagocytosed Escherichia coli and Staphylococcus aureus.
    Adinolfi LE; Utili R; Dilillo M; Tripodi MF; Attanasio V; Ruggiero G
    J Antimicrob Chemother; 1989 Dec; 24(6):927-35. PubMed ID: 2695512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628.
    Anderson R; Jooné GK
    Chemotherapy; 1993; 39(6):424-31. PubMed ID: 8222871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of ciprofloxacin on the phagocytosis of Escherichia coli by human polymorphonuclear leukocytes].
    Pérez P; Herrera I; Martín M; Gómez-Lus ML; Prieto J
    Enferm Infecc Microbiol Clin; 1993 Oct; 11(8):411-4. PubMed ID: 8260511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli.
    Mascellino MT; Iona E; Iegri F; De Gregoris P; Farinelli S
    FEMS Immunol Med Microbiol; 1993 Jun; 7(1):23-8. PubMed ID: 8364519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of synergistic activity between ciprofloxacin and broad snouted caiman serum against Escherichia coli.
    Siroski PA; Russi NB; Ortega HH; Formentini EA
    Res Vet Sci; 2015 Feb; 98():98-105. PubMed ID: 25468795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of intracellular growth of Mycobacterium fortuitum by human monocytes in vitro.
    Nziramasanga P; Shah PM; Stille W
    J Chemother; 1993 Apr; 5(2):103-6. PubMed ID: 8515290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.
    Horwitz MA; Silverstein SC
    J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC; Smith JT
    Microbios; 1994; 80(322):31-9. PubMed ID: 7854197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of aminoglycosides against phagocytosed bacteria.
    Utili R; Adinolfi LE; Dilillo M; Tripodi MF; Marrone A; Ruggiero G
    J Antimicrob Chemother; 1991 Dec; 28(6):897-904. PubMed ID: 1816186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and biochemical changes in Escherichia coli after exposure to ciprofloxacin.
    Diver JM; Wise R
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():31-41. PubMed ID: 3542947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131.
    Johnson JR; Porter SB; Thuras P; Johnson TJ; Price LB; Tchesnokova V; Sokurenko EV
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7132-5. PubMed ID: 26324269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro influence of charcoal on ciprofloxacin activity.
    Torre D; Sampietro C; Quadrelli C; Bianchi W; Maggiolo F; Ohnmeiss H
    Drugs Exp Clin Res; 1988; 14(5):333-4. PubMed ID: 3065019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of mutation at amino acid 45 of AcrR to acrB expression and ciprofloxacin resistance in clinical and veterinary Escherichia coli isolates.
    Webber MA; Talukder A; Piddock LJ
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4390-2. PubMed ID: 16189130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Sep; 28(3):399-405. PubMed ID: 1660046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Characterization of Genes That Contribute to High-Level Ciprofloxacin Resistance in Escherichia coli.
    Tran T; Ran Q; Ostrer L; Khodursky A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6353-5. PubMed ID: 27431218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.